TRANSGENE SA

Their core work

Transgene is a French biotechnology company specializing in immunotherapy, particularly the design and development of therapeutic vaccines and oncolytic viruses for cancer and infectious diseases. Within H2020, they contribute preclinical and nonclinical expertise to consortia working on vaccine development, immune safety assessment, organ-on-a-chip platforms, and single-cell analysis of tumour resistance. Their participation spans from TB vaccine advancement to computational immunology and tumour cell persistence studies, reflecting a consistent focus on translating immunological insights into therapeutic strategies.

What they specialise in

How they've shifted over time

In the early phase (2015–2018), Transgene's H2020 work centred on infectious disease vaccines (TBVAC2020) and in vitro tissue engineering platforms like organ-on-a-chip for drug development and toxicity screening (EUROoC). From 2019 onward, their focus shifted decisively toward cancer immunotherapy — computational immunology, immune safety modelling (imSAVAR), and single-cell multi-omics approaches to understand tumour resistance (PERSIST-SEQ). This evolution tracks the broader industry move from traditional preclinical models toward data-rich, patient-derived experimental systems.

Transgene is moving toward precision immuno-oncology, combining computational modelling with single-cell multi-omics to understand why tumours resist therapy — expect future work at the intersection of AI-driven immunology and personalised cancer treatment.

How they like to work

Transgene consistently participates as a partner rather than leading consortia — zero coordinator roles across four projects. They join large, multi-country consortia (101 unique partners across 19 countries), suggesting they contribute specialised industry expertise to academic-led research efforts. This profile is typical of a pharma/biotech company that brings translational and preclinical capabilities to collaborative research without taking on coordination overhead.

Transgene has collaborated with 101 unique partners across 19 countries, indicating a broad European network built through large health-focused consortia. Their base near Strasbourg places them at the Franco-German research corridor, with connections spanning Western and Northern Europe.

What sets them apart

Transgene brings a rare combination: they are an established biotech company with deep immunotherapy expertise who actively participates in academic-scale research consortia. Unlike pure research institutes, they offer a direct translational pathway from preclinical findings toward therapeutic products. Their recent pivot into single-cell omics and computational immunology positions them as a partner who can bridge wet-lab immunology with data-driven approaches — valuable for any consortium needing industry-grade preclinical validation.

Highlights from their portfolio

• PERSIST-SEQ
  Represents Transgene's most advanced technical engagement — single-cell sequencing, spatial transcriptomics, and patient-derived organoids to crack tumour resistance, running until 2026.
• imSAVAR
  Directly addresses immune safety of immunomodulatory therapies using computational immunology and microphysiological systems — core to Transgene's identity as an immunotherapy company.
• TBVAC2020
  Their earliest H2020 project, advancing TB vaccine candidates from discovery to preclinical stages — shows Transgene's roots in infectious disease before their cancer immunotherapy pivot.